OPKO Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OPKO Health, Inc. on April 14, 2014. The report discloses a specific corporate governance event regarding executive compensation approved by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the grant of stock options and does not contain financial performance data.
Material Changes
The material change reported is the grant of stock options to named executive officers. The options vest ratably over four years and expire on the tenth anniversary of the grant date. The specific grants are as follows:
- Phillip Frost, M.D. (CEO & Chairman): 400,000 shares
- Jane H. Hsiao (Vice Chairman & Chief Technical Officer): 350,000 shares
- Steven D. Rubin (Executive Vice President - Administration): 350,000 shares
- Adam Logal (Sr. Vice President, Chief Financial Officer): 250,000 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on future performance, risks, contingencies, or unusual items beyond the standard disclosure of the compensation grant.
Investor Verification Points
- Verify the strike price of the granted stock options, which is not disclosed in this text.
- Confirm the total number of shares authorized for issuance under the company's equity incentive plan.
- Review the vesting schedule details to ensure the "ratably over four years" term aligns with the company's standard policy.
- Check for any subsequent filings regarding the exercise or expiration of these specific options.